Phaseline

Companies › Rhizen Pharmaceuticals

Rhizen Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tenalisib (RP6530)
PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor
PIK3CD, PIK3CGPhase 2Triple Negative Breast Cancer (TNBC)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06189209Tenalisib (RP6530)Phase 2Triple Negative Breast Cancer (TNBC)OncologyDec 2026

Targets

PIK3CD (1) PIK3CG (1)

Companies with the same targets

SecuraBio Incyte Biosciences Japan GK Pharming Technologies Incyte Kyowa Kirin Restorbio Celcuity Eli Lilly Sovargen Stelexis BioSciences

Companies built like this

SecuraBio Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.